There are an increasing number of clinical trials involving targets such as CD5, CD7, CD19, CD20, CD22, CD33, CD38, CD70, HER2, Mesothelin, Muc1, NKG2D ligands, PD-1, PD-L1, PSMA, ROBO1, CD19/CD22, CD33/CLL1, CD38/SLAMF7, NKG2D(NKG2D-CD8-DAP12-CAR) (NCT03415100), FT536 (hnCD16/CD38KO/anti-MICA/B CAR/IL-15RF), for hematological malignancies and solid tumors [29, 174, 191]. The gene discussed is SLAMF7; the disease is hematologic disorder.